Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial

Open access
Shi, Ming, Li, Yuan-Yuan, Xu, Ruo-Nan, Meng, Fan-Ping, Yu, Shuang-Jie, Fu, Jun-Liang, Hu, Jin-Hua, Li, Jing-Xin, Wang, Li-Feng, Jin, Lei, Wang, Fu-Sheng · 2021 · Hepatology International

Published version of a preprint

Abstract

Background: Mesenchymal stem cell (MSC) infusion was reported to improve liver function in patients with decompensated liver cirrhosis (DLC); however, whether the medication can improve outcome of these patients is poorly understood. Methods: This prospective, open-labeled, randomized controlled study enrolled 219 patients with HBV-related DLC who were divided into control group ( n = 111) and umbilical cord-derived MSC (UC-MSC)-treated group ( n = 108), then all of them received a follow-up check from October 2010 to October 2017. The treated patients received three times of UC-MSC infusions at 4-week intervals plus conventional treatment that was only used for control group. The overall survival rate and HCC-free survival rate were calculated as primary endpoints and the liver function and adverse events associated with the medication were also evaluated. Results: During the follow-up check period from 13 to 75th months, there was a significantly higher overall survival rate in the treated group than the control group, while the difference of the hepatocellular carcinoma event-free survival rate between the treated and control groups was not observed during the 75-month follow-up. UC-MSC treatment markedly improved liver function, as indicated by the levels of serum albumin, prothrombin activity, cholinesterase, and total bilirubin during 48 weeks of follow-up. No significant side effects or treatment-related complications were observed in the UC-MSC group. Conclusions: Therapy of UC-MSC is not only well tolerated, but also significantly improves long-term survival rate, as well as the liver function in patients with HBV-related DLC. UC-MSC medication, therefore, might present a novel therapeutic approach for the disease. Graphic abstract:

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12072-021-10199-2

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Protocol for UC-MSC treatment in HBV-related decompensated liver cirrhosis patients. UC-MSC transfusions were administered to the patients three times: at the baseline (0 weeks), at 4 weeks, and at 8 weeks. The clinical parameters were tested at 0, 12, 24, and 48 weeks after the treatment. For survival analysis, the follow-up was prolonged to 75 months. All participants received the same conventional treatment throughout the study
Fig. 1 Protocol for UC-MSC treatment in HBV-related decompensated liver cirrhosis patients. UC-MSC transfusions were administered to the patients three times: at the baseline (0 weeks), at 4 weeks, and at 8 weeks. The clinical parameters were tested at 0, 12, 24, and 48 weeks after the treatment. For survival analysis, the follow-up was prolonged to 75 months. All participants received the same conventional treatment throughout the studyCC BY · PubMed Central
Fig. 2 Study flow diagram. A total of 252 patients with decompensated liver cirrhosis were enrolled, but two patients were excluded: one refused to participate, and one did not meet the inclusion criteria. Therefore, 250 patients were randomized into the control and umbilical cord-derived mesenchymal stem cell (UC-MSC) treatment groups, with 125 patients in each group. In the control group, ten patients withdrew the consent, four patients were lost to follow-up, and in the UC-MSC treatment group, ten patients withdrew the consent, seven patients were lost to follow-up. Therefore, 111 control patients and 108 UC-MSC-treated patients were followed up for 75 months and analyzed in the trial
Fig. 2 Study flow diagram. A total of 252 patients with decompensated liver cirrhosis were enrolled, but two patients were excluded: one refused to participate, and one did not meet the inclusion criteria. Therefore, 250 patients were randomized into the control and umbilical cord-derived mesenchymal stem cell (UC-MSC) treatment groups, with 125 patients in each group. In the control group, ten patients withdrew the consent, four patients were lost to follow-up, and in the UC-MSC treatment group, ten patients withdrew the consent, seven patients were lost to follow-up. Therefore, 111 control patients and 108 UC-MSC-treated patients were followed up for 75 months and analyzed in the trialCC BY · PubMed Central
Fig. 3 Disease-free survival rate in patients with HBV-related decompensated liver cirrhosis treated with UC-MSC infusion or the conventional therapeutic regimen. a Disease-free survival rate in the UC-MSC treatment group and control group. b Landmark analysis for comparing survival before 13 months and beyond 13 months (up to 75 months) of follow-up
Fig. 3 Disease-free survival rate in patients with HBV-related decompensated liver cirrhosis treated with UC-MSC infusion or the conventional therapeutic regimen. a Disease-free survival rate in the UC-MSC treatment group and control group. b Landmark analysis for comparing survival before 13 months and beyond 13 months (up to 75 months) of follow-upCC BY · PubMed Central
Fig. 4 Influence of UC-MSC treatment on liver function in decompensated liver cirrhosis patients. a Serum albumin, b prothrombin activity, c cholinesterase, d total bilirubin. *p < 0.05, **p < 0.01 compared with the baseline values; ##p < 0.01 compared with the control group at the corresponding time point
Fig. 4 Influence of UC-MSC treatment on liver function in decompensated liver cirrhosis patients. a Serum albumin, b prothrombin activity, c cholinesterase, d total bilirubin. *p < 0.05, **p < 0.01 compared with the baseline values; ##p < 0.01 compared with the control group at the corresponding time pointCC BY · PubMed Central
Fig. 5 HCC event-free rate in patients with HBV-related decompensated liver cirrhosis treated with UC-MSC infusion or the conventional treatment protocol. a HCC event-free rate in the UC-MSC treatment group and control group. b Landmark analysis for comparing survival before 8 months and during 8–75 months of follow-up
Fig. 5 HCC event-free rate in patients with HBV-related decompensated liver cirrhosis treated with UC-MSC infusion or the conventional treatment protocol. a HCC event-free rate in the UC-MSC treatment group and control group. b Landmark analysis for comparing survival before 8 months and during 8–75 months of follow-upCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 152

Metadata

Authors
Shi, M., Li, Y.-Y., Xu, R.-N., Meng, F.-P., Yu, S.-J., Fu, J.-L., Hu, J.-H., Li, J.-X., Wang, L.-F., Jin, L., & Wang, F.-S.
Affiliations
Chinese PLA General Hospital (CN)
Corresponding author
  • Shi, Ming
  • Wang, Fu-Sheng
Venue
Hepatology International
Published
2021-11-29
Volume
15
Issue
6
Pages
1431-1441
ISSN
  • 1936-0533 (ISSN-L)
  • 1936-0541
OpenAlex
W3166597897
Cited by
151
References
32
Citations by year
2026: 25 · 2025: 39 · 2024: 35 · 2023: 35 · 2022: 17
FWCI
12.22
Type
journal article
Language
en
Open access
Licence
Locations
  • Hepatology International (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • the National Key R&D Program of China (2017YFA0105703)
  • National Natural Science Foundation of China (82070617)
  • Innovative Research Group Project of the National Natural Science Foundation of China (81721002)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
mesenchymal stem cells, umbilical cord-derived stem cells, decompensated cirrhosis, HBV-related liver cirrhosis, stem cell therapy, overall survival, liver function, long-term follow-up, treatment safety
MeSH terms
Follow-Up Studies, Humans, Liver Cirrhosis, Prospective Studies, Treatment Outcome, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.